Albumins belong to the group of plasma proteins. Albumins serve as transport proteins in the blood and are responsible for the colloid osmotic pressure of blood plasma. They are, for instance, used to stabilize the blood circulation volume in the event of strong bleeding.
| Name | Marketing Authorisation Holder | License Number | License Date | Further Information |
|---|---|---|---|---|
|
Albiomin 5% |
Biotest Pharma GmbH |
PEI.H.03575.01.1 | 22.06.2007 | |
|
Albiomin 20% |
Biotest Pharma GmbH |
PEI.H.03574.01.1 | 22.06.2007 | |
|
Albumeon |
CSL Behring GmbH |
PEI.H.11655.01.1 | 24.05.2013 | |
|
Albunorm 4% |
Octapharma GmbH |
PEI.H.04333.05.1 | 20.07.2015 | |
|
Albunorm 5% |
Octapharma GmbH |
PEI.H.04333.01.1 | 26.03.2009 | |
|
Albunorm 20% |
Octapharma GmbH |
PEI.H.04333.02.1 | 26.03.2009 | |
|
Albunorm 25% |
Octapharma GmbH |
PEI.H.04333.06.1 | 20.07.2015 | |
|
Alburex 5 |
CSL Behring GmbH |
PEI.H.11429.01.1 | 25.01.2010 | |
|
Alburex 20 |
CSL Behring GmbH |
PEI.H.11429.02.1 | 25.01.2010 | |
Albutein 50 g/l |
Grifols Deutschland GmbH |
PEI.H.12090.01.1 | 26.08.2021 | |
Albutein 200 g/l |
Grifols Deutschland GmbH |
PEI.H.12090.02.1 | 26.08.2021 | |
Crealb 200g/l |
Prothya Biosolutions Netherlands B.V. |
PEI.H.12044.02.1 | 24.09.2020 | |
HUMAN ALBUMIN 50g/l Baxalta |
Takeda GmbH |
PEI.H.03271.01.1 | 01.04.2006 | |
|
HUMAN ALBUMIN 200g/l Baxalta |
Takeda GmbH |
PEI.H.03272.01.1 | 01.04.2006 | |
|
HUMAN ALBUMIN 250g/l Baxalta |
Takeda GmbH |
PEI.H.03273.03.1 | 12.10.2023 | |
|
Human-Albumin 20% Behring, salzarm |
CSL Behring GmbH |
10530a/96 | 27.01.1997 | |
|
Humanalbumin 200 g/l Kedrion |
KEDRION S.p.A. |
PEI.H.02994.01.1 | 12.12.2003 | |
|
Plasbumin 20 |
Grifols Deutschland GmbH |
4962.01.00 | 06.08.1984 | |
|
Plasbumin 25 |
Grifols Deutschland GmbH |
10537a/96 | 26.05.1999 |
The list of medicines contains the products that have a valid marketing authorization. It contains no information as to whether the preparations are available on the market.
The information contained in the Federal Gazette, which is the official publication organ of the Paul-Ehrlich-Institut, is legally binding.
As of: PEI announcement No. 530 in BAnz AT 16.06.2025 B4.
Where the European Medicines Agency (EMA) offers further information, you will find a link to the EPAR (European public assessment report) in the table.
If user and technical information or public assessment reports are available in PharmNet.Bund, the Federal and State Pharmaceutical Information Portal, these are directly linked to PharmNet.Bund in the table.
Updated: 17.06.2025
